What is your preferred systemic treatment for patients progressing during or soon after completion of consolidation durvalumab for unresectable NSCLC?
Community PollStarted
What is your preferred systemic treatment for patients progressing during, or soon after completion of, consolidation durvalumab for unresectable NSCLC in the absence of a targetable mutation?
57 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · University Hospitals Seidman Cancer Center and Case Western Reserve University
Answered on
This is an excellent question for which (to my knowledge) no randomized prospective data is available. As this is a frequent clinical scenario, one would hope that investigators in the thoracic oncology field would perform such a study in the future. That being said, I can see the rationale for givi...
Join for free or sign in to see the full answer
Mednet Member
Medical Oncology · Emory University School of Medicine
Answered on · Updated on
If platinum resistant, I would offer docetaxel, ramucirumab, and pembrolizumab on clinical trial NCT04340882.
Join for free or sign in to see the full answer